What This Article Covers
This article summarizes published research on TB-500 for technical review. It separates direct human evidence, review-level context, and animal or mechanistic work so the reader can see what has actually been tested before seeing the limitations.
- Nomenclature and heterogeneity: TB-500 is a label used for thymosin beta-4 (Tβ4)–related peptides. Analytical work has identified an N-terminal acetylated 17–23 fragment of Tβ4 in some products marketed as TB-500, particularly in doping-control contexts; product composition may vary and these findings should not be presumed universal across all products [semantic:10.1002/dta.1402]. These analytical data inform detection/regulatory discussions, not demonstrated efficacy.
- Evidence mix in the evidence set: The evidence set includes one PubMed human-context study in a vascular injury/restenosis setting (pathway-focused, not TB-500 administration) [pubmed:39873228], alongside a scoping review preprint [crossref:10.20944/preprints202605.1124.v1] and multiple reviews and preclinical/mechanistic sources. Reviews frame biological plausibility and translational context but do not replace primary human outcome evidence [pubmed:41490200; pubmed:17468232; pubmed:17495248; pubmed:41476424; pubmed:38994967].
- Measurement caveat: Quantifying circulating Tβ4 shows assay-related variability; biomarker claims should be made cautiously [pubmed:29502471].
- Scope: Conclusions below are confined to the supplied sources. Dosing, standardized safety, long-term outcomes, and broad efficacy/generalizability are not established in this evidence set.
Bottom Line
- TB-500 is best understood as a Tβ4-related product; some marketed materials have been analytically identified as an N-acetylated Tβ4 17–23 fragment, but composition can vary. Much of the literature addresses endogenous Tβ4 biology rather than specific TB-500 formulations [semantic:10.1002/dta.1402].
- The evidence set contains narrow, context-specific human evidence tied to Tβ4-related pathways in a vascular injury/restenosis setting; this should not be interpreted as interventional efficacy data for TB-500 and should remain anchored to the studied population and endpoints [pubmed:39873228].
- Most cited sources are reviews or preclinical/mechanistic; they provide rationale and hypotheses but do not establish clinical utility for TB-500 [pubmed:41490200; pubmed:17468232; pubmed:17495248; pubmed:41476424; pubmed:22074294].
- No randomized or controlled interventional human trials of TB-500 are identified in the supplied evidence set.
What Was Tested in Humans?
No controlled human intervention data were identified in the available evidence set used for this draft. That does not mean the compound has no research interest; it means human outcome claims should not be made from this article’s source base.
What Did Animal and Mechanistic Studies Show?
The available evidence set should be interpreted carefully when it includes animal, cellular, formulation, or mechanistic findings. Those findings can explain why researchers study the compound, but they should not be presented as established human outcomes.
How the Evidence Fits Together
The practical reading for TB-500 is evidence hierarchy. Human studies, when present, carry the most weight, but only for the exact population, route, comparator, and endpoint studied. Reviews can help map the field, and animal or mechanistic studies can explain biological plausibility, but neither should be used to leap beyond the human evidence.
What Is Not Established
- Broad human efficacy for TB-500 is not established by this article.
- Animal, cellular, or review-level findings should not be converted into human-use claims.
- Dosing, administration, treatment, diagnostic, or veterinary-use guidance is outside the scope of KRL materials.
Research-Use Boundary
This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.
Selected Sources
– [pubmed:39873228]
- Human-context study (pathway/biological context; not TB-500 administration):
– [pubmed:41490200], [pubmed:41476424], [pubmed:17468232], [pubmed:17495248], [pubmed:38994967], [pubmed:27450728], [pubmed:27450736], [pubmed:29502471], [crossref:10.20944/preprints202605.1124.v1]
- Reviews/translational and methods context:
– [pubmed:22074294], [pubmed:12852258], [crossref:10.1016/j.peptides.2007.01.004], [semantic:10.1002/dta.1402]
- Preclinical/mechanistic and analytical:
– [pubchem:62707662], [patent_search:tb-500-tb500-thymosin-beta-4-thymosin-4]
- Identifiers/registries (not efficacy evidence):
Related KRL Resources
Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.
1st Time Customers Receive 10% off their 1st order over $100.00 with CODE KRL10
Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.